Arcturus expands collaboration, adding $30M cash; Kura shoots for $100M raise
→ Rare disease player Ultragenyx $RARE is expanding its alliance with Arcturus $ARCT, paying $24 million for equity and another $6 million in an upfront as the two partners expand their collaboration to include up to 12 targets. “This expanded collaboration further solidifies our mRNA platform by adding additional targets and expanding our ability to potentially treat more diseases,” said Emil Kakkis, the CEO at Ultragenyx. “We are pleased with the progress of our ongoing collaboration. Our most advanced mRNA program, UX053 for the treatment of Glycogen Storage Disease Type III, is expected to move into the clinic next year, and we look forward to further building upon the initial success of this partnership.”
→ It’s only 7 patients, but Therapix Biosciences $TRPX couldn’t wait to tout an interim analysis of its oral drug for obstructive sleep apnea. The data suggest that THX-110 has induced “significant improvement” in 4 patients and mild improvement in 1.